AbbVie
ABBV
3,371 hedge funds and large institutions have $217B invested in AbbVie in 2024 Q2 according to their latest regulatory filings, with 154 funds opening new positions, 1,472 increasing their positions, 1,317 reducing their positions, and 125 closing their positions.
33% more call options, than puts
Call options by funds: $2.77B | Put options by funds: $2.09B
23% more first-time investments, than exits
New positions opened: 154 | Existing positions closed: 125
12% more repeat investments, than reductions
Existing positions increased: 1,472 | Existing positions reduced: 1,317
0.55% more ownership
Funds ownership: 71.12% → 71.67% (+0.55%)
0% less funds holding
Funds holding: 3,387 → 3,371 (-16)
5% less capital invested
Capital invested by funds: $228B → $217B (-$11.5B)
21% less funds holding in top 10
Funds holding in top 10: 223 → 177 (-46)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$979M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$796M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$499M |
| 4 |
Goldman Sachs
New York
|
+$451M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$374M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$1.57B |
| 2 |
BlackRock
New York
|
-$1.08B |
| 3 |
Bank of New York Mellon
New York
|
-$382M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$163M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$135M |
ABBV Hedge Fund Activity: Q2 2024 in Review
3,371 of the 6,936 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2024, worth a combined $217B — down 5% from $228B a quarter earlier.
Buyers outnumbered sellers: 154 funds opened new ABBV positions and 125 closed out — a net gain of 29 holders — while 1,472 added to existing stakes and 1,317 trimmed.
The largest buyer was Capital World Investors, adding an estimated $979M. The largest seller was Capital International Investors, cutting an estimated $1.57B.
- 3,371 institutional investors held AbbVie (ABBV) as of Q2 2024, down from 3,387 in Q1 2024.
- Funds reported $217B of AbbVie stock for Q2 2024, down 5% quarter-over-quarter.
- 154 funds opened new AbbVie positions in Q2 2024 and 125 closed out, a net change of +29 holders.
- The largest AbbVie buyer in Q2 2024 was Capital World Investors, an estimated $979M added.
- The largest AbbVie seller in Q2 2024 was Capital International Investors, an estimated $1.57B sold.
Based on aggregated 13F filings for Q2 2024.